Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares.
View SPPI analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month price objectives for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they anticipate the company's stock price to reach $2.44 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.07. During the same quarter in the prior year, the firm earned ($0.37) earnings per share.

IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio.

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

One share of SPPI stock can currently be purchased for approximately $1.03.

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $211.41 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405.